Background and rationale
========================

Coronary artery disease (CAD) leads to substantial morbidity and mortality. Control of the CAD epidemic will require a multifaceted strategy including primary prevention maneuvers -- some designed for the general population and some targeting only high-risk individuals, and secondary prevention maneuvers targeted at those with established disease. Many of the risk factors for CAD are modifiable and improving these risk factors has been shown to reduce the subsequent occurrence of myocardial infarction (MI) or death in patients with CAD. In particular, there is strong evidence supporting the following five therapies or maneuvers for secondary prevention in patients with CAD: statins (cholesterol lowering drugs), smoking cessation, antiplatelet agents, beta-blockers, and ACE (angiotensin converting enzyme) inhibitors.

Statins
-------

Large-scale epidemiologic studies have shown there is a strong, consistent and graded relationship between cholesterol levels and mortality from CAD \[[@B1]\]. A series of 11 randomized trials (Table [1](#T1){ref-type="table"}) \[[@B2]-[@B12]\] over the past decade have confirmed that initiating statin therapy in patients with CAD reduces the occurrence of vascular events; indeed, the relative risk reductions appear to be independent of baseline cholesterol levels, at least in the range of cholesterols tested in the trials. Two other large trials \[[@B13],[@B14]\] targeted patients for primary prevention of MI and, although they may well have included some patients with occult CAD, are not included in Table [1](#T1){ref-type="table"}. The only large statin trial that failed to demonstrate a statistically significant benefit with statin use (ALLHAT-LLT) was likely contaminated by very high rates of statin use in the \"control\" arm of that trial\[[@B15]\]. A meta-analysis of these trials confirmed that statins are clearly beneficial for secondary prevention in all subgroups of CAD patients, including those with LDL cholesterol levels ≤ 2.5 mmol/L and those without prior MI\[[@B16]\].

###### 

Features of randomized statin secondary prevention trials designed to detect differences in clinically important end-points

  **Trial**                                 **Treatment (mg/day) andFollow-up Duration**                     **Key Eligibility Criteria**                                                                                                                       **Number of Patients**   **Mean Age (yrs)**   **% Change in LDL-c**                        **Relative Risk Reduction, Mortality and MI (95% CI)**
  ----------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ -------------------- -------------------------------------------- --------------------------------------------------------
  **4S \[2\]**                              Simvastatin 20 mg for 5.4 yrs (median)                           35--70 yrs, prior angina or AMI, fasting total cholesterol 5.5--8.0 mmol/L                                                                         4444                     58.6                 -35%                                         30% (15% to 42%) and 27% (20% to 34%)
  **LIPID \[3\]**                           Pravastatin 40 mg for 6.1 yrs (mean)                             31--75 yrs, prior AMI or unstable angina, fasting total cholesterol 4 -- 7 mmol/L                                                                  9014                     62                   -25%                                         22% (13% to 31%) and 29% (18% to 38%)
  **CARE \[4\]**                            Pravastatin 40 mg for 5.0 yrs (median)                           21--75 yrs, prior AMI, fasting LDL cholesterol 3.0--4.5 mmol/L                                                                                     4159                     59                   -28%                                         9% (-12% to 26%) and 25% (8% to 39%)
  **MRC/BHF Heart Protection Study\[5\]**   Simvastatin 40 mg for 5.0 yrs (mean)                             40--80 yrs, increased risk of CV death (due to known atherosclerotic disease, or diabetes, or hypertension with other CV risks)                    20 536                   NR                   -29%                                         13% (6% to 19%) and 27% (21% to 33%)
  **MIRACL \[6\]**                          Atorvastatin 80 mg for 16 weeks (mean)                           18 -- 77 yrs, ACS, screening cholesterol \<7.0 mmol                                                                                                3086                     65                   -52%                                         6% (-31% to 33%) and 10% (-16% to 31)
  **LIPS \[7\]**                            Fluvastatin 80 mg for 3.9 yrs (median)                           18 -- 80 yrs, after percutaneous intervention, screening cholesterol 3.5--7.0 mmol                                                                 1677                     60                   -27%                                         31% (17% to -14%) and 19% (62% to -24%)
  **PROSPER\[8\]**                          Pravastatin 40 mg for 3.2 yrs (mean)                             70--82 yrs, with vascular disease or at high risk, screening cholesterol 4.0--9.0 mmol/L                                                           5804                     75                   -34%                                         3% (17% to -14%) and 14% (-3% to +28%)^1^
  **ASCOT \[9\]**                           Atorvastatin 10 mg for 3.3 yrs (median)                          40--79 yrs, hypertension plus \>3 other cardiovascular risk factors, screening cholesterol ≤ 6.5 mmol/L                                            10 305                   63                   -35%                                         13% (29% to -6%) and 36% (17% to 50%)
  **PROVE IT-TIMI 22 \[10\]**               Atorvastatin 80 mg vs. Pravastatin 40 mg for 2.0 yrs (mean)      \> 18 yrs, ACS, screening cholesterol ≤ 6.21 mmol/L or 5.18 mmol/L if on lipid lowering therapy                                                    4162                     58.3                 Atorva: -42% Prava: -10%                     28% (-2% to +50%) and 13% (-8% to 32%)^1^
  **TNT \[11\]**                            Atorvastatin 80 mg vs. Atorvastatin 10 mg for 4.9 yrs (median)   35--75 yrs, stable CAD, LDL-c \< 3.4 mmol/L                                                                                                        10 001                   61                   Atorva 80 mg: -21% Atorva 20 mg: no change   -1% (-19% to +15%) and 22% (7% to 34%)^1^
  **IDEAL \[12\]**                          Atorvastatin 80 mg vs. Simvastatin 20 mg for 4.8 yrs (median)    18--80 years, prior AMI                                                                                                                            8888                     62                   Atorva : -34% Simva : -17%                   2% (-13% to 15%) and 17% (2% to 29%)^1^
  **ALLHAT-LLT \[15\]**                     Pravastatin 40 mg for 4.8 yrs (mean)                             Hypertension, older than 55 years, at least one other cardiac risk factor and LDL-c 3.1--4.9 mmol/L without known CAD or 2.6--3.3 with known CAD   10 355                   66                   -17%                                         1% (-11% to +11%) and 9% (-4% to +21%)

1\. Based on hazard ratio; LDL-c= LDL cholesterol; CAD = coronary artery disease; AMI = acute myocardial infarction; ACS = acute coronary syndrome; CV = cardiovascular; Atorva = atorvastatin; Prava = Pravastatin; Simva = simvastatin.

Smoking cessation
-----------------

Cigarette smokers with CAD are at increased risk for MI -- relative risks range from 1.4 to 2.2 in cohort studies\[[@B1]\]. There is evidence that smoking cessation lowers the risk of recurrent myocardial infarction by almost 50% within 2 years,\[[@B17]\] and systematic reviews have shown that one-time advice from physicians during routine office visits increases the annual rate of smoking cessation by 2%. Interventions such as bupropion and/or nicotine replacement therapies may also increase cessation rates. \[[@B18]-[@B20]\] Patients with symptomatic CAD may be even more receptive to smoking cessation advice, with up to one-third quitting smoking after acute MI\[[@B21]\].

Antiplatelet agents
-------------------

The Antithrombotic Trialists\' Collaboration\[[@B22]\] included 27 trials in 39,308 patients with a history of MI: meta-analysis of the data confirmed that aspirin conferred a 23% relative reduction in subsequent rates of MI, stroke, or vascular death. This systematic review also included 53 trials in 17,394 patients with CAD but no prior MI: the relative risk reduction with aspirin was 30% for vascular events.

Beta-blockers
-------------

A systematic review of 55 trials in MI survivors demonstrated a convincing survival benefit with beta-blockers (RRR 25%), irrespective of baseline clinical risk factors\[[@B23],[@B24]\]. Although beta-blockers have not been shown to be more efficacious than long-acting calcium-channel blockers or nitrates in those CAD patients without a history of MI (a systematic review of 90 comparative trials)\[[@B25]\], there is some data suggesting that beta-blockers reduce cardiac morbidity and mortality in CAD patients without prior MI. \[[@B26]-[@B31]\] Guidelines from the American College of Physicians, the American Heart Association, and the American College of Cardiology recommend the use of beta-blockers as first-line therapy for angina in patients without contraindications\[[@B32]\]. Thus, a case can be made for recommending beta-blockers in all CAD patients who have already suffered a MI or who are symptomatic, unless contraindicated.

ACE inhibitors
--------------

The Heart Outcomes Prevention Evaluation (HOPE) trial showed that compared to placebo, ramipril reduced cardiovascular events (nonfatal MI, stroke, or vascular death) by 22% in high-risk patients 55 years or older with evidence of vascular disease or diabetes, plus one other cardiovascular risk factor\[[@B33]\]. The relative efficacy was similar in the 7477 patients with known CAD, irrespective of whether they had already suffered a MI or not. Similar benefits with ACE inhibition in CAD patients were seen in the EURopean trial On Reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA)\[[@B34]\] and the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)\[[@B35]\]. Although the placebo-controlled PEACE (Prevention of Events with Angiotensin-Converting Enzyme Inhibitor) trial \[[@B36]\] did not find a reduction in cardiovascular morbidity or mortality with trandolapril, participants\' cardiovascular risk factors were so well controlled at baseline in the PEACE trial that the event rates in the placebo group were far lower than in the HOPE, EUROPA, or SCAT studies -- and were sufficiently low enough so that the study was under-powered to detect a significant benefit in the ACE inhibitor arm. Thus, it seems reasonable to recommend that ACE inhibitors be strongly considered for patients with CAD and without contraindications, particularly those with suboptimal control of risk factors such as LDL (low-density lipoprotein) cholesterol -- the very patients of interest in the ESP-CAD trial described below.

### Coronary artery disease: missed opportunities for secondary prevention

Despite the abundant evidence base for secondary prevention, practice audits consistently demonstrate substantial \"care gaps\" between this evidence and clinical reality, in that many patients with CAD are not offered all possible opportunities for the secondary prevention of MI or death (see Table [2](#T2){ref-type="table"}). For example, even after an acute MI, almost one-fifth of patients with CAD continue to smoke, more than half with hypertension or hyperlipidemia have poorly controlled blood pressures or lipid levels, and proven efficacious therapies such as antiplatelet agents, beta-blockers, ACE inhibitors, and statins are under-prescribed. \[[@B37]-[@B50]\] Even those patients that receive therapies (i.e. statins) rarely achieve the recommended target levels for the treated risk factor, either due to suboptimal dose titration or poor patient adherence (statin persistence has been shown to range from 43% to 75% at one year). \[[@B51]-[@B53]\] Importantly, these \"care gaps\" are linked to poor patient outcomes, and closure of these care gaps improves prognosis\[[@B39],[@B54]\]. Clearly, a means to help translate this evidence into clinical practice is urgently required.

###### 

Provision of proven efficacious therapies in patients with CAD, multi-centre studies since 1995

  **Setting (ref)**                                                                                          **Sample Size**   **Statin Use**   **ACE InhibitorUse**   **Beta-blockerUse**   **Antiplatelet Use**   **Current Smokers**   **% with cholesterol at or below target\***
  ---------------------------------------------------------------------------------------------------------- ----------------- ---------------- ---------------------- --------------------- ---------------------- --------------------- ---------------------------------------------
  ***Audits from General Practices:***                                                                                                                                                                                                    
  Canada (42)                                                                                                4315              38%              NR                     NR                    53%                    25%                   14%
  Canada (43)                                                                                                NR                NR               NR                     NR                    54%                    NR                    NR
  USA (46)                                                                                                   11 745            NR               NR                     21%                   NR                     NR                    NR
  UK (41)                                                                                                    1921              NR               10%                    32%                   63%                    18%                   17%
  UK (44)                                                                                                    24 431            16%              13%                    22%                   50%                    24%                   56%
  Canada (49)                                                                                                3721              100%             NR                     NR                    NR                     17%                   73%
  International REACH Registry (50)                                                                          40 258            76%              51%                    63%                   86%                    13%                   NR
  ***Audits in patients discharged after acute myocardial infarction or coronary artery bypass surgery:***                                                                                                                                
  USA (39)                                                                                                   201 752           NR               30%                    34%                   83%                    NR                    NR
  USA (37)                                                                                                   1710              12%              NR                     44%                   53%                    NR                    NR
  USA (38)                                                                                                   622               37%              NR                     23%                   46%                    25%                   15%
  USA (45)                                                                                                   190 015           NR               31%                    NR                    NR                     NR                    NR
  USA (47)                                                                                                   25 000            NR               NR                     NR                    81%                    NR                    NR
  Europe (40)                                                                                                3379              58%              43%                    66%                   84%                    21%                   41%
  Ontario(48)                                                                                                9667              40%              65%                    68%                   NR                     NR                    NR
  Quebec(48)                                                                                                 4790              43%              57%                    68%                   NR                     NR                    NR
  British Columbia(48)                                                                                       2570              42%              58%                    61%                   NR                     NR                    NR
  Nova Scotia(48)                                                                                            761               36%              58%                    83%                   NR                     NR                    NR
  Alberta (APPROACH patients)\*\*                                                                            5104              34%              39%                    61%                   81%                    NR                    NR

Note that while the general practice audits represent cross-sectional data at varying times after the diagnosis of CAD, the audits in patients discharged after acute MI generally represent prescribing data between 90 days and 120 days after MI.

\* Target cholesterol defined as LDL cholesterol ≤ 2.6 mmol/L or total cholesterol ≤ 5.0 mmol/L.

\*\* Medications in use at the time of the cardiac catheterization (no data available on prescriptions in follow-up). \[Colleen Norris, personal communication, August 2003\]

### Current strategies to close care gaps are often ineffective

In examining why care gaps are present, it has consistently been shown that multiple barriers (patient-, physician-, and health care system-related) are often responsible for the lack of implementation of proven efficacious therapies and traditional means of educating practitioners (journal articles, continuing medical education conferences, grand rounds lectures, *et cetera*) are usually ineffective in altering practice\[[@B55],[@B56]\]. Disease management programs employing specialized clinics or multidisciplinary teams have been shown to improve the management of patients with CAD; however, these programs are often difficult to implement on a widespread scale and are only available for a minority of eligible patients\[[@B57]\]. Simpler, cheaper, and more effective means of increasing the prescribing of proven therapies for CAD patients are needed.

### The potential role of point-of-care reminders and opinion leaders in closing care gaps

In looking for a simple, effective and evidence-based means to improve the quality of care for patients with CAD, we have isolated 2 key elements -- point-of-care reminders and educational materials endorsed by local opinion leaders that form the basis of the quality improvement intervention to be tested in this trial\[[@B58]\].

The interface between hospital-based specialists and community-based primary care physicians is frequently imperfect, and this system barrier likely affects the quality of care for patients with CAD. Reminder systems, particularly those which are clear, patient-specific, and delivered at the point of care, can improve communication and the delivery of health services in numerous settings, although the effects are often modest\[[@B59]\]. A recent systematic review, however, concluded that the effects of point-of-care reminders sent by specialists to primary care physicians had been inadequately evaluated\[[@B59]\].

This is particularly significant because surveys of primary care physicians consistently confirm the importance of colleagues and local consultants on patterns of practice\[[@B60],[@B61]\]. In fact, several recent studies suggest that the mere provision of evidence without specialist input, even with a point-of-care reminder at the time patients are being seen, may not be enough to change practice in CAD. For example, although the mailing of patient-specific reminders (from the local health authority) about secondary prevention therapies to the primary care physicians of MI survivors in England led to higher rates of cholesterol measurement and recording of cardiac risk factors in these patients, there was no appreciable difference in statin prescribing rates\[[@B62]\]. Similarly, faxing care management summary sheets (listing diagnoses, medications, pertinent laboratory data, and guideline recommendations for each patient) to the primary care physicians of patients with diabetes and dyslipidemia did not significantly impact statin prescription rates\[[@B63]\]. Finally, four trials testing the effects of computerized decision support systems that prompted primary care practitioners with reminders and management guidelines (which were not explicitly endorsed by local opinion leaders) when they were seeing patients with CAD reported negligible improvements in prescribing of statins or other proven efficacious therapies compared to controls. \[[@B64]-[@B67]\]

Local opinion leaders are well-known, respected health care professionals who are trusted by their peers to evaluate medical innovations within the local context. \[[@B68]-[@B70]\]. Since they influence patterns of practice in the community, their participation in any program of quality improvement is essential. Yet, the use of local opinion leaders to influence physician practice has only been tested in 10 randomized trials\[[@B69],[@B71],[@B72]\]. While eight of the nine trials that measured practice patterns showed some improvements with opinion leaders, only three demonstrated statistically significant benefits. \[[@B72]-[@B74]\] All three of these trials assessed labour-intensive, expensive, hospital-based educational interventions spearheaded by a small number of opinion leaders for inpatient conditions (delivery by cesarean section, treatment of acute MI, and treatment of unstable angina). A tenth trial evaluated the impact of a multifaceted intervention that included physician and nurse opinion leaders (as two of the 10 factors included in the intervention) on management of patients with acute MI. They demonstrated improvements in some of their quality indicators, however, it is impossible to gauge the efficacy of opinion leaders alone in this study\[[@B54]\]. Although the use of local opinion leaders to influence the outpatient management of common conditions (such as CAD) holds great promise, as of yet this is a promise unfulfilled, and a hypothesis that needs to be tested.

### Interventions must be practical to influence community-based practice

When testing the effect of local opinion leaders in the outpatient setting, the generalizability of the intervention is of utmost concern. Thus, the focus must be on a practical means of incorporating the influence of these individuals into everyday practice. Previous studies have established that the information format favoured most by front-line clinicians is a one-page summary of guidelines or evidence\[[@B60],[@B75]\]. Moreover, two studies have established that specific guidelines are substantially more effective in influencing physician behaviour than non-specific guidelines\[[@B76],[@B77]\]. Finally, there is speculation that providing objective proof of disease (e.g., a coronary angiogram report), along with the evidence, may enhance the impact of the evidence with physicians. However, whether such a picture really is worth a 1,000 words has never been rigorously evaluated in a randomized trial.

### Work preceding this trial

With these considerations in mind, we surveyed all primary care physicians in Edmonton and Calgary, Canada and asked them to nominate local opinion leaders for CAD in each region, using a previously validated sociometric survey tool as described fully elsewhere\[[@B68],[@B78]\]. These local opinion leaders agreed to participate in this project and worked in concert with clinical epidemiologists to generate and endorse one-page evidence summaries and treatment recommendations for the management of patients with CAD (hereafter referred to as the \"Local Opinion Leader Statement\"**-**see [Additional file 1](#S1){ref-type="supplementary-material"}). We chose to emphasize statins in the Local Opinion Leader Statement because we felt the evidence base for statins in patients with CAD was robust and applicable to virtually all patients with CAD (see Table [1](#T1){ref-type="table"}). The recommendations will be distributed to the primary care physician by fax, along with patient-specific coronary angiogram results. This will act as both a source of credible and convincing information and a specific reminder for action at the next patient encounter.

Local opinion leaders are not always self-evident and conducting surveys to identify them for each condition and in each locale would be difficult. Thus, it is important to be certain that any benefits seen with a local opinion leader-based intervention are truly due to the local opinion leader (the messenger) and not just the message. For that reason, we have included a third arm in our trial which will involve exposure to a quality improvement initiative that is identical in every respect to the local opinion leader statement -- but without the local opinion leader signature (hereafter referred to as \"Unsigned Evidence Statement\" -- see [Additional file 2](#S2){ref-type="supplementary-material"}). Of note, this arm of the study will essentially duplicate the typical point-of-care reminder studies discussed earlier. \[[@B63]-[@B67]\]

### Aim of the study

This trial is designed to test two interventions for improving the quality of care for patients with established CAD. The principal hypothesis to be tested is: Does a local opinion leader-based quality improvement intervention influence primary care physicians to increase the provision of secondary prevention therapies in their patients with known CAD compared to usual care? The secondary hypotheses to be tested are: (1) Does the same quality improvement intervention, but without explicit local opinion leader endorsement (i.e., without the local opinion leaders\' signatures), improve the provision of secondary prevention maneuvers in CAD patients compared to usual care? And, (2) does local opinion leader endorsement increase the effectiveness of the quality improvement intervention?

Methods
=======

Study design
------------

The study design is a randomized clinical trial testing three different intervention policies: Usual care versus Local Opinion Leader Statement versus Unsigned Evidence Statement (see Trial Flow in Figure [1](#F1){ref-type="fig"}). The target population is patients with CAD proven on coronary angiography. As there is a potential for a physician or a group practice of physicians to have patients randomized to more than one arm of the study, cluster randomization at the level of the practice will be employed to avoid contamination. \[[@B79]\] Thus, this represents the optimal design for evaluating quality improvement interventions\[[@B80]\].

![Trial Flow Proposed patient enrollment and randomization procedures.](1748-5908-1-11-1){#F1}

Details of the intervention
---------------------------

The Local Opinion Leader Statement is a one-page summary of evidence-based secondary prevention strategies and treatment recommendations for patients with CAD, and contains the signatures of all five CAD local opinion leaders identified by our survey of primary care practitioners (see [Additional file 1](#S1){ref-type="supplementary-material"}). The emphasis is on statin prescribing -- as a result, statins are recommended first (listing only those statins which have been proven efficacious in large trials), and the letter explicitly mentions their starting and target doses, usual titration schedules, and monitoring parameters. For each of the other secondary prevention therapies (ACE inhibitors, antiplatelet agents, beta-blockers), we list only the drug class in the Opinion Leader Statement without explicit statements about dosing, titration, or monitoring parameters.

The Local Opinion Leader Statement will be imprinted with the name of the patient and addressed directly to the primary care physician. The statement will be faxed to the physician following the completion of the patient\'s coronary angiogram along with objective evidence of the patient\'s CAD (the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease \[APPROACH\] HeartView Diagram which documents the extent of the patient\'s coronary atherosclerosis)\[[@B81]\]. All of the faxes (APPROACH HeartView diagrams and the one page statement) will be generated and sent automatically using a software program that has been developed for this trial and embedded in the APPROACH software. It is intended that the statement and the HeartView Diagram will become part of the patient\'s medical record and will serve as a reminder for action at the next patient visit.

The Unsigned Evidence Statement, identical to the Local Opinion Leader Statement in content but without the local opinion leader signatures (see [Additional file 2](#S2){ref-type="supplementary-material"}), will be faxed to the primary care physician, along with the APPROACH HeartView Diagram, in the same manner as described above.

Physicians of control patients (usual care) will receive a fax containing only the APPROACH Heartview Diagram. This will ensure that all physicians and patients receive the same number of study related materials and encounters, with the only difference being the content of the fax.

Study setting
-------------

All three cardiac catheterization laboratories in the province of Alberta, Canada (total population 3.1 million people) are participating in this trial.

Study participants
------------------

Eligible patients (and their primary care physicians) will be identified by the research assistants at the time of their cardiac catheterization and approached for written informed consent to participate in the study. Specific criteria for inclusion and exclusion include the following:

### Inclusion criteria

Alberta residents older than age 18 who undergo a cardiac catheterization and are diagnosed with CAD on the basis of coronary angiography, demonstrating a stenosis in at least one coronary vessel of ≥ 50%\[[@B82]\].

### Exclusion criteria

Patients will be excluded if: (1) they have not had a fasting lipid panel done in the six weeks prior to their cardiac catheterization; (2) they are already on a statin at maximal dose; (3) they are on a statin/lipid-lowering drug and the LDL cholesterol level is ≤ 2.5 mmol/l; (4) they are not on a statin but their fasting LDL is ≤ 1.8 mmol/L; (5) they do not have CAD proven on catheterization; (6) they are undergoing catheterization in the setting of an acute coronary syndrome or cardiogenic shock; (7) they die during the catheterization or require emergency bypass surgery; (8) the catheterization is being done as part of a research protocol; (9) they do not have an identifiable primary care physician; (10) they have contraindications to statin use (history of cirrhosis or inflammatory muscle disease, serum creatinine ≥ 200 umol/L, women of child-bearing age, or prior allergy to statins); and/or (11) they are already enrolled in ESP-CAD.

Allocation to experimental arms
-------------------------------

Randomization will take place 1:1:1 at the level of the practice (either individual physician for solo practitioners or clinic for those physicians who practice in a group setting) following the completion of the patient\'s coronary angiogram using a \'real-time\' central randomization system with allocation concealment embedded in the APPROACH software. After a practice\'s first patient is randomized, all subsequent patients from that practice will be assigned to whatever treatment arm the first patient was randomized to.

While this is a form of cluster randomization, we anticipate the design effect to be negligible since the majority of physicians will contribute no more than one or two study patients, and thus all sample size and analytic considerations use the patient as the unit of analysis and the unit of causal inference.

Outcome measures
----------------

We decided to focus on only those secondary prevention maneuvers that have strong evidence of survival benefits and are readily measurable from patient self-report and/or examination of pharmacy records. We decided not to examine factors (such as blood pressure control or LDL cholesterol levels) that would require in-person patient assessments, as this would substantially increase the complexity and expense of this study. If the interventions tested in this study are effective, then subsequent studies will extend the interventions (and their assessment) to address other cardiovascular risk factors such as control of blood pressure.

Although we mention five secondary prevention maneuvers in the local opinion leader and unsigned evidence statements (see Additional Files [1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}), we chose to emphasize statin prescribing in the statements (and as our primary outcome measure) because we felt the evidence for using statins in all patients with CAD (regardless of baseline cholesterol level) is more robust than the evidence for the use of ACE inhibitors or beta-blockers in all patients. Although the evidence in support of antiplatelet agents also is robust, we chose not to make this the primary outcome because of the likelihood that ASA prescribing may be close to maximal already (see Table [2](#T2){ref-type="table"}).

### Primary outcome

The primary outcome measure is a composite measure representing improvement in statin-related secondary prevention consisting of: 1) provision of a statin sample, or 2) provision of a statin prescription, or 3) increasing the dosage of a statin within the first six months post-angiogram. As this is a composite end-point, only the first event attained in the cluster will be counted for analysis, although all events will be recorded in the database.

Six months was chosen for the primary and secondary outcomes because the average number of physician visits in our audit of trial-eligible patients attending the University of Alberta cardiac catheterization laboratory in the 2003 year was 1.8 visits in six months. As we are assessing the impact of the Local Opinion Leader Statement and Unsigned Evidence Statement on physician practice patterns, for the purposes of this study we are interested solely in evaluating attempted practice change. In other words, if a patient is provided with a statin sample or a statin prescription, or the dosage is increased by any of the patient\'s physicians, it would still count as a positive outcome for the main study analysis, even if the patient cannot tolerate the medication and discontinues it or is noncompliant during follow-up. We recognize that patient (and physician) long-term compliance with preventive therapies is important, and will collect data on persistence rates with secondary prevention maneuvers over the six months of the study. We anticipate that this data will serve as pilot data for a planned future study on interventions to improve provider/patient persistence rates.

We will examine the primary outcome rates in all three treatment arms as follows: the primary comparison will be between those patients randomized to the Local Opinion Leader Statement versus usual care, and the secondary comparisons will be (a) between those patients randomized to the Unsigned Evidence Statement versus usual care, and (b) between those patients randomized to the Local Opinion Leader Statements versus Unsigned Evidence Statements.

### Secondary outcomes

Secondary outcomes will include the provision of other proven efficacious medications for CAD by six months, including ACE inhibitors, beta-blockers, and antiplatelet agents; these medications will be considered independently as individual end-points in eligible patients. Moreover, we will examine changes in the provision of other lipid-lowering medications (fibrates, niacin, and/or resins), as well as self-reported smoking rates, receipt of smoking cessation advice, provision of nicotine replacement products, or buproprion in trial patients within six months of their angiogram. We also will record whether study participants have a fasting lipid profile done in the six months post-angiogram and, for the subgroup of patients who have a fasting lipid profile done during follow-up (i.e., done for clinical reasons by their attending physicians, [not]{.ul}mandated by the trial protocol), we will examine the proportion of patients achieving target LDLs compared to baseline. Finally, we also will analyze clinical events (MI, stroke, admissions for CAD, total hospitalizations, and mortality) in the three arms of this study, although the study is not powered to find any differences in these end-points over such a short timeframe.

Study procedures and data collection
------------------------------------

Baseline data (including demographics, comorbidities, medication use, cholesterol levels, and sociodemographic variables) will be collected by research personnel using a standardized abstraction instrument at the time of the patient\'s catheterization. The primary source of outcome data for the study will be patient self-report on telephone contact at three and six months, with cross-referencing to pharmacy records for medications, centralized laboratory data for fasting lipid panels, and medical records for clinical outcomes. In an earlier study, we found a high degree of agreement between patient self-report of statin and ACE inhibitor use and data from dispensing pharmacies (simple agreements ranged between 88% to 99% and kappas were 0.78 to 0.93)\[[@B83]\]. Vital status will be queried via the APPROACH database. The outcome data will be abstracted using standardized forms in a secure database housed in the Epidemiology Coordinating and Research (EPICORE) Centre, University of Alberta, Canada.

Investigators, outcome assessors, and study patients will be masked to allocation status. Primary care physicians cannot be blinded to allocation status. Follow-up data will be collected without knowledge of allocation status in an independent and blinded fashion, and statistical analyses will be conducted by a statistician blinded to allocation status.

Sample size
-----------

In a survey of 22 members of the divisions of cardiology and general internal medicine at the University of Alberta, we determined that the \"minimal\" clinically important difference for this particular intervention to be considered useful was a 15% absolute improvement over and above usual care. After six months, we estimate that no more than 20% of control patients will have attained our composite primary outcome, given that patients who are already on a statin and have optimal LDL cholesterol levels will be excluded from this study at baseline. We calculated our sample size to detect a 15% absolute increase in the primary outcome, set the α error rate at 0.05 (2-sided), and the β error at 0.20 (power 80%) -- this yielded a sample size of 138 patients per study arm. Allowing for losses during follow-up, the ability to examine each of the conditions separately, and the possibility of a very small design effect associated with patient clustering, the total sample size has been adjusted upwards to 160 patients per arm (480 in total).

Statistical analyses
--------------------

Intention-to-treat analyses will be carried out with patients as the unit of analysis. Although the physician will be the unit of allocation, we anticipate a very small design effect, and the outcomes for individual patients will be clinically and statistically independent of each other.

The primary outcome will first be tested using the chi square statistic to compare the attainment of our primary statin outcome within six months in patients randomized to the Local Opinion Leader Statement versus patients randomized to the Unsigned Evidence Statement. If the impact of the Local Opinion Leader Statement is significantly different from that of the Unsigned Evidence Statement, we will compare each to usual care separately. If the impact of the Local Opinion Leader Statement and the Unsigned Evidence Statement are similar, we will combine data from both arms and compare this with usual care, which will essentially be a test of point-of-care reminders versus usual care.

In order to investigate what factors are associated with changes in the primary outcome (our dependent binary variable), and to control for the possibility of potential imbalances in patient-level characteristics at baseline, multivariable logistic regression analyses will be used to examine those variables that are deemed to be clinically important (i.e., age, gender) or that differ statistically at a p-value \< 0.10 between study arms. In addition, to examine the possibility of \"cluster-associated\" study design effects, two sensitivity analyses will be considered. First, the main analysis will be repeated using the physician as the unit of analysis. Second, the aforementioned logistic regression models will be reanalyzed using generalized estimating equations to control for the potential lack of statistical independence among patients treated by the same study physician\[[@B84]\].

There will be one pre-planned interim analysis to explore event rates in all three study arms after 80 patients per arm have reached the six month primary outcome time-point. We are primarily interested in examining whether projected event rates are correct, or whether the sample size will need to be adjusted upwards, and will employ the Haybittle-Peto stopping rule using a Z value of 3.0 for this interim test. For the main study analysis, we will consider a p-value \< 0.05 to be statistically significant.

### Other analyses

In examining the secondary outcomes (for example, use of ACE inhibitors, beta-blockers, etc.), we will use similar statistical methods for the primary statin outcome analyses.

Data management
---------------

All data will be collected using standardized data sheets and data collation, entry and quality assurance will be carried out in the Epidemiology Coordinating and Research (EPICORE) Centre, Division of Cardiology, University of Alberta.

Ethical considerations
----------------------

Each patient will be given written information about the study and written informed consent will be obtained prior to study entry. Although the physicians receiving our study faxes will not be explicitly informed that they are in a trial at the time of the fax, we did inform all physicians with privileges within participating health authorities at the time of the opinion leader survey that a trial testing novel strategies to communicate evidence for patients with coronary artery disease would be conducted in the near future. On the survey form eliciting the opinion leaders, we gave all physicians the option to indicate if they did not want to participate in this future region-wide program to improve prescribing practices for CAD. Those who declared they did not want to participate were excluded from ESP-CAD eligibility. Thus, any patients of these physicians will not be enrolled in ESP-CAD. Furthermore, it should be noted that as part of the process of obtaining privileges within the participating health authorities (the Capital Health Authority in Edmonton and the Calgary Health Region) physicians sign a consent form to participate in \"peer review and clinical quality improvement programs\" within the health authorities, and such forms are updated every three years.

The study protocol has been approved by the Health Research Ethics Board, University of Alberta, Edmonton, Alberta (file number: 5082) and the Conjoint Health Research Ethics Board, University of Calgary, Calgary, Alberta (ethics ID: E-20129). The funding for the study is from three peer-reviewed grants. The funding sources (the Alberta Heritage Foundation for Medical Research, the Heart and Stroke Foundation of Canada, and Pfizer Canada) had no role in the design of the study and will have no role in its conduct, analysis, interpretation, or reporting -- and will not have access to the data. None of the local opinion leaders received any financial compensation for their participation in the study or endorsement of the evidence summaries.

Discussion
==========

We report the protocol of a cluster randomized trial that aims to determine the effect of a feasible and readily generalizable evidence-based quality improvement initiative for patients with CAD. Local opinion leaders are potentially powerful tools for quality improvement, and our proposed method of defining a role for them in cardiovascular disease should lead to improved care for patients. In addition, this trial will establish whether the APPROACH computer system can be used as a novel vehicle for identifying and delivering secondary prevention interventions to high-risk patients with CAD. If our interventions are effective, they can be widely and easily applied in other communities, particularly in the future as APPROACH extends beyond the borders of Alberta, as well as for other target conditions.
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